Press Releases
September 14, 2021
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
July 19, 2021
ROME Therapeutics Expands Science Leadership in Oncology, Data Science and New Target Discovery
March 1, 2021
ROME Therapeutics announces the appointment of Scott Biller, Ph.D. to its board.
September 28, 2020
ROME Therapeutics announces that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies
August 19, 2020
ROME Therapeutics Appoints Drug Discovery Veteran Dennis Zaller, Ph.D., as Chief Scientific Officer
April 27, 2020
ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessing the Power of the Repeatome